RxDoctor Payments Data

Christine Grap

Nurse Practitioner · Baltimore, MDNPI 1609425453

Payments from drug & device makers

$1,163in general payments, 2019–2025

Across 46 payments — averaging $25.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Harmony Biosciences LLC$220
  • Inspire Medical Systems, Inc.$151
  • Novo Nordisk$149
  • Axsome Therapeutics, Inc.$142
  • Avadel CNS Pharmaceuticals, LLC$86
  • Lilly USA, LLC$77
  • plus $339 from 8 others

What the payments were for

  • Food & beverage$1,14999%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,163 in reported general payments places this provider in the 85th percentile of 1,562 nurse practitioner providers in Maryland.

See all nurse practitioner providers in Maryland

Medicare billing

Part B allowed, 2024
$59,523
Medicare patients
264
Services billed
705

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide18$29,928
OzempicSemaglutide21$28,910
EliquisApixaban18$25,477
JanuviaSitagliptin Phosphate11$17,239
JardianceEmpagliflozin22$17,154
Levothyroxine Sodium141$2,033
Atorvastatin Calcium140$1,982
Albuterol Sulfate HfaAlbuterol Sulfate44$1,883
Rosuvastatin Calcium74$1,773
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,456
Gabapentin49$1,327
SynthroidLevothyroxine Sodium22$1,317
Esomeprazole Magnesium14$934
Pantoprazole Sodium48$829
Lisinopril90$784

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$149$58,83839 claims
Boehringer IngelheimJardiance$41$17,15422 claims
AbbVieSynthroid$62$1,31722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,562 nurse practitioner providers in Maryland.

Other nurse practitioner in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →